The treatment of leukemia involves various cancer therapies and long-term courses of specific medications. There are many forms of treatment for leukemia and most of them have pronounced side-effects. Although the medical treatments available today are effective in achieving complete remission, they also trigger serious undesirable effects among patients with leukemia. Considering this fact, medical scientists nowadays focus on improving the efficiency of cancer medications with minimal side-effects.

The improved version of the leukemia drug ATRA (all-trans retinoic acid) is considered to be a safer and a more reliable alternative to prolonged chemotherapy and traditional cancer medications. The enhanced version of the drug ATRA is Lipo-ATRA, a more advanced and effective cancer medication. Unlike the old version of the drug, the active agent of Lipo-ATRA is covered with a layer a fat. Its inventors claim that Lipo-ATRA remains inside the human body for longer periods of time, thus having increased efficiency in fighting leukemia cells. In addition, Lipo-ATRA can be administered intravenously, allowing the drug to act a lot quicker in fighting the disease. Thanks to its long-term action, Lipo-ATRA can also minimize the risks of relapse.

During the trial period, Lipo-ATRA has proved to be very effective in overcoming acute myelogenous leukemia (AML). Patients with AML that have been administered the enhanced version of ATRA have experienced a complete remission and they have remained asymptomatic for long periods of time. The majority of patients with AML have even exceeded the critical five-year period of remission, thus being completely cured.

Medical scientists are very satisfied with the potential and the safety of the new drug. They sustain that Lipo-ATRA is a reliable replacement for traditional chemotherapy. Medical scientists explain that more than a third of patients with acute myelogenous leukemia who receive Lipo-ATRA can be spared of prolonged chemotherapy. Considering the fact that the new drug acts very well on its own, patients often don't require other adjutant cancer therapies or treatments.

In the trial period, the new drug Lipo-ATRA was tested on 34 patients with acute myelogenous leukemia (AML). In the initial stages of treatment, Lipo-ATRA was administered along with idarubicin, a strong cancer medication. When patients began to achieve remission, Lipo-ATRA was administered without idarubicin. The effects of Lipo-ATRA were remarkable, as 10 patients among the 34 that participated to the study remained in remission for more than 5 years even after they stopped receiving adjutant chemotherapy drugs.

Thanks to its efficiency in curing leukemia and thanks to its fewer side-effects, Lipo-ATRA is considered to be the best option in overcoming the disease in present. An appropriate substitute for traditional chemotherapy, Lipo-ATRA may soon revolutionize the treatment of leukemia.